Platform / Technology · 02

One engineered cell. Three systems.

We don’t bolt a single fix onto a generic cell. The platform integrates manufacturing, navigation and safety so a single engineered cell can reach a solid tumour, get inside, persist, and act — without the toxicity that keeps therapy in the hospital.

Pre-clinical Non-viral Tumour-agnostic engine
The thesis

Each barrier has its own answer.
All of them live in one cell.

Trafficking, infiltration, persistence and safety are usually tackled in isolation. Gaisce treats them as one engineering problem — a single construct whose systems reinforce one another rather than competing for space inside the cell.

Fig. 01BacPac · Non-viral manufacturing
01 · INTEGRATED PAYLOAD — ONE CONSTRUCT NAV SAFETY DURABLE LARGE-PAYLOAD CAPACITY 02 · NON-VIRAL DELIVERY NO VECTOR 03 · ENGINEERED T-CELL
SchematicOne integrated payload — three engineered modules — delivered without a viral vector.
S-01

BacPac™

The launch vehicle

BacPac is our non-viral manufacturing system — the vehicle that carries the full engineered package into the cell. Designing for large payload capacity without viral vectors is what makes the rest of the platform possible to build and, eventually, to scale.

  • ApproachNon-viral delivery of a large engineered payload
  • Why it mattersCapacity for an integrated multi-system construct
  • IntentA path toward biologic, not service, economics

Biologic economics, not service economics.

Fig. 02STNAV · Solid-tumour navigation
01 · HOMING — FIND THE TARGET 02 · INFILTRATION — BREACH & ENTER OUTSIDE INSIDE 03 · SURVIVAL — WITHSTAND ENTRY
SchematicHoming, infiltration and survival traced as one continuous route into the tumour.
S-02

STNAV™

The solid-tumour breaker

STNAV is the navigation system — homing, infiltration and survival, integrated so the cell finds the tumour, gets inside, and withstands the hostile microenvironment on entry. It is designed as a tumour-agnostic engine rather than a one-target fix.

  • HomingDirects the cell toward the tumour bed
  • InfiltrationEngineered to enter where others are locked out
  • SurvivalWithstands the microenvironment after entry

A tumour-agnostic homing engine.

Fig. 03Stayble-T · Durability & safety
01 · DURABILITY — SUSTAINED ACTIVITY SUSTAINED TIME → 02 · AUTONOMOUS SAFETY — TGF-β GATING CYTOTOXIC INTENSITY TGF-β SENSITIVITY KILL INTENSITY TUNES TGF-β RESPONSE 03 · OUTPATIENT-READY
SchematicSustained activity with a self-limiting safety loop gated by cytotoxic intensity.
S-03

Stayble‑T™

The market unlock

Stayble-T pairs intrinsic durability with autonomous safety. The cell continuously tunes its own TGF-β sensitivity to how intensely it is killing — so the response self-limits without external intervention. That self-regulation is what moves the therapy toward the outpatient setting: the difference between a treatment and an accessible one.

  • DurabilitySustained activity over time, by design
  • SafetyAutonomous TGF-β sensitivity, gated by cytotoxic intensity
  • GoalAn outpatient-ready treatment profile

Engineered to be outpatient-ready.

Fig. 04Switch receptors · Signal inversion
01 · SUPPRESSIVE MICROENVIRONMENT IL-10 IL-4 TGF-β 02 · SWITCH RECEPTOR − + SIGNAL INVERTED 03 · STIMULATORY GO SIGNAL + +
SchematicSuppressive cytokines re-read as activating signals at the membrane.
S-03 · Detail

Switch receptors

Stayble-T · Suppression, inverted

Durability isn’t only about lasting — it’s about thriving where the tumour fights back. The solid-tumour microenvironment switches T-cells off with cytokines like IL-10, IL-4 and TGF-β. Stayble-T’s switch receptors are engineered so those same suppressive signals are read as activating ones — the cell is driven on precisely where others are turned off.

  • InputsIL-10 · IL-4 · TGF-β — normally immunosuppressive
  • InversionSuppressive binding is converted to a stimulatory signal
  • OutcomeHostile terrain becomes a source of activation

Suppression becomes signal.

Lead construct

A receptor chosen for breadth.
A signal chosen for tolerability.

Our lead construct, GB-001, is a tumour agnostic asset with first target indication of second-line and later metastatic colorectal cancer. It pairs broad, multi-ligand recognition with a signalling architecture selected for a cleaner tolerability profile than first-generation designs.

We frame these as engineering decisions, not claims — each made against a named failure mode, each carried forward only when the data clears our bar.

See how the platform de-risks
every named failure mode.

Our approach View the pipeline

We are supported by